interviews
July 1, 2011 source: Genetic Engineering & Biotechnology News by Brad Webb Rapid Transition from Laboratory Discoveries to Commercialization Is Transforming Healthcare It’s been less than a decade since a full human genome was sequenced, but already there is talk that the promise of genomics-inspired personal medicine is not being realized. I couldn’t disagree more. […]
Read MoreJune 22, 2011 source: Genetic Engineering and Biotechnology News On June 10, a day after withdrawing an $86 million IPO filed in November 2010, Ambit Biosciences reported securing $30 million in Series D-2 equity financing. “The terms currently obtainable in the public marketplace are not sufficiently attractive to the registrant to warrant proceeding with the […]
Read MoreQ&A with Nat Goldhaber on the Three Mile Island crisis By Peter Delevett Mercury News Columnist Nat Goldhaber may have the most offbeat resume of any venture capitalist in Silicon Valley. In early 1979, he was a few weeks into a job running energy policy for Pennsylvania’s new governor — a post for which he cheerfully […]
Read MoreJohn Steuart was a panelist at The Deal’s webcast audio seminar: Technology Transfer in the 21st Century, on May 12, 2011 (also participating as a panelist – Jeff Jensen, CEO, Fluxion Biosciences Inc. a Claremont Creek Ventures portfolio company) A recording of the seminar is now available to play online or download through 8/12/2011. Click […]
Read MoreNat Goldhaber, managing director of Claremont Creek Ventures in Oakland, said a monster showing by BrightSource could spark a “Google effect” that leaves investors as enthusiastic about pioneering energy firms as they have been about information technology. May 3, 2011 source: New York Times BrightSource Energy Inc.’s plan to go public this year could spur […]
Read More
April 21, 2011 source: Gigaom When it comes to clean-energy investing 2.0, venture capitalists are beyond looking for the silver bullet — or the magic battery –- they spent the last decade hunting and hoping for. Today, VCs are more likely to invest their dollars in slightly less ambitious energy-efficiency projects, Paul Kedrosky, senior fellow […]
Read MoreMeet our team
Claremont Creek Ventures was founded in 2005 by Nat Goldhaber, John Steuart and Randy Hawks to pursue early stage investing in exceptional technology startups.
NAT GOLDHABER
Nat Goldhaber is a co-founder of Claremont Creek Ventures.
BRAD WEBB
Brad is focused on the role of genomics and biomarker data analytics in driving the next generation of diagnostics and drug development.
RANDY HAWKS
Randy Hawks is a co-founder of Claremont Creek Ventures.